A resveratrol derivative RVX-208 inhibits PD-1/PD-L1 to restrain non-small cell lung cancer as an immunotherapy
{{output}}
Immunotherapies, particularly anti-PD-1 antibodies, have emerged as standard first-line treatments for non-small cell lung cancer (NSCLC). RVX-208, derived from resveratrol, has recently completed Phase III clinical trials for atherosclerosis in the United Sta... ...
